ORMP

MKT CAP:$155M

Oramed Pharmaceuticals Inc.

Market Cap

$155M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.84+$0.93 (+31.96%)

Apr 23, 2026

Company Details

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship prod...

CEO

Nadav Kidron

IPO Date

May 1, 2007

Website

www.oramed.com

Key Metrics TTM

Revenue

$2M

— YoY

Net Income

$44M

EPS (Diluted)

$0.99

Free Cash Flow

-$11M

Revenue / Share

$0.05

Gross Margin

-4.0%

Operating Margin

-650.5%

Net Margin

2192.6%

FCF Margin

-551.4%

P/S

77.6x

P/E

3.5x

Earnings Reports

Q3 2025

Nov 13, 2025

$0EPS $1.13

Q2 2025

Aug 14, 2025

$0EPS $0.31

Q1 2025

May 15, 2025

$2MEPS -$0.19

FY 2024

Mar 27, 2025

$0-100.0%EPS -$0.47

Q4 2024

Mar 27, 2025

$0EPS -$0.26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$665.0K	$665.0K	-$5M
Q2 21	$681.0K	$681.0K	-$6M
Q3 21	$683.0K	$683.0K	-$7M
Q1 22	$666.0K	$666.0K	-$11M
Q2 22	$674.0K	$674.0K	-$11M
Q4 22	$681.0K	$681.0K	-$10M
Q2 23	$674.0K	$674.0K	-$4M
Q3 23	$0	$0	-$3M
Q4 23	$0	$0	-$4M
Q1 24	$0	$0	-$3M
Q2 24	$0	$0	-$3M
Q3 24	$0	$0	-$3M
Q4 24	$0	-$31.0K	-$4M
Q1 25	$2M	$13.0K	-$5M
Q2 25	$0	-$30.0K	-$2M
Q3 25	$0	-$31.0K	-$2M

Valuation

Quarter	P/S	P/E
Q1 21	100.2x	—
Q2 21	123.7x	—
Q3 21	209.3x	—
Q1 22	130.3x	—
Q2 22	64.9x	—
Q4 22	141.4x	—
Q2 23	53.1x	—
Q3 23	51.2x	—
Q4 23	72.9x	262.1x
Q1 24	172.0x	11.1x
Q2 24	—	5.0x
Q3 24	—	22.3x
Q4 24	—	—
Q1 25	43.8x	—
Q2 25	46.0x	—
Q3 25	56.4x	2.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$3M	-$4M
Q2 21	-$6M	-$6M
Q3 21	-$6M	-$6M
Q1 22	-$10M	-$10M
Q2 22	-$8M	-$8M
Q4 22	-$8M	-$8M
Q2 23	-$3M	-$3M
Q3 23	-$545.6K	-$573.3K
Q4 23	-$1M	-$1M
Q1 24	-$1M	-$1M
Q2 24	$2M	$2M
Q3 24	-$7M	-$7M
Q4 24	-$2M	-$2M
Q1 25	-$4M	-$4M
Q2 25	-$4M	-$4M
Q3 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q1 21	$40.8K
Q2 21	$2.2K
Q3 21	$28.6K
Q1 22	$47.0K
Q2 22	$18.5K
Q4 22	$295.3K
Q2 23	$16.5K
Q3 23	$27.6K
Q4 23	$2.0K
Q1 24	$2.0K
Q2 24	$17
Q3 24	$5.0K
Q4 24	$11.0K
Q1 25	$3.0K
Q2 25	$4.0K
Q3 25	$289

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	-1.3%	+17.4%
Q2 21	+0.0%	+130.1%
Q3 21	+0.3%	+118.8%
Q1 22	-1.2%	+83.3%
Q2 22	+1.4%	+118.5%
Q4 22	+0.0%	+53.3%
Q2 23	-1.3%	-44.8%
Q3 23	-100.0%	-75.7%
Q4 23	-100.0%	-67.9%
Q1 24	-100.0%	-71.6%
Q2 24	-100.0%	-29.8%
Q3 24	—	+6.8%
Q4 24	—	-7.3%
Q1 25	—	+119.4%
Q2 25	—	-20.6%
Q3 25	—	-21.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$0	0.0%
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q4 22	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$0	—
Q2 24	$0	—
Q3 24	$0	—
Q4 24	$0	—
Q1 25	$2M	109.5%
Q2 25	$0	—
Q3 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 21	$4M	$2M	—
Q2 21	$6M	$1M	—
Q3 21	$6M	$2M	—
Q1 22	$6M	$5M	$590.0K
Q2 22	$9M	$3M	$380.0K
Q4 22	$7M	$3M	$418.0K
Q2 23	$2M	$2M	$192.0K
Q3 23	$957.0K	$3M	—
Q4 23	$2M	$2M	—
Q1 24	$1M	$2M	—
Q2 24	$1M	$2M	—
Q3 24	$2M	$847.0K	—
Q4 24	$1M	$2M	—
Q1 25	$2M	$2M	—
Q2 25	$1M	$1M	—
Q3 25	$1M	$1M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$28M	$114M	$142M
Q2 22	$30M	$104M	$134M
Q3 22	$33M	$126M	$160M
Q4 22	$40M	$115M	$156M
Q1 23	$24M	$130M	$154M
Q2 23	$7M	$143M	$150M
Q3 23	$5M	$170M	$175M
Q4 23	$9M	$153M	$162M
Q1 24	$19M	$158M	$177M
Q2 24	$85M	$68M	$153M
Q3 24	$42M	$100M	$142M
Q4 24	$54M	$88M	$142M
Q1 25	$75M	$56M	$131M
Q2 25	$16M	$82M	$98M
Q3 25	$52M	$83M	$135M
Q4 25	$46M	$5M	$51M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	27M	+13.7%	+51.6%
Q2 21	30M	+10.8%	+28.9%
Q3 21	30M	0.0%	+28.9%
Q1 22	39M	+29.2%	+62.8%
Q2 22	39M	+0.3%	+43.7%
Q4 22	39M	+0.5%	+30.3%
Q2 23	40M	+3.1%	+34.4%
Q3 23	40M	+0.5%	+4.6%
Q4 23	41M	+0.1%	+4.4%
Q1 24	42M	+2.6%	+6.6%
Q2 24	42M	+0.1%	+3.4%
Q3 24	41M	-1.7%	+1.1%
Q4 24	40M	-2.4%	-1.4%
Q1 25	41M	+3.3%	-0.8%
Q2 25	43M	+3.3%	+2.4%
Q3 25	43M	+0.4%	+4.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	$55.4K	12
Q2 21	$56.8K	12
Q3 21	$52.5K	13
Q1 22	$51.2K	13
Q2 22	$51.8K	13
Q4 22	$40.1K	17
Q2 23	$39.6K	17
Q3 23	$0	17
Q4 23	$0	15
Q1 24	$0	15
Q2 24	$0	15
Q3 24	$0	15
Q4 24	$0	15
Q1 25	$133.3K	15
Q2 25	$0	15
Q3 25	$0	15

Revenue / Employee